Frankfurt
24.04.25
09:15 Uhr
5,600 Euro
+0,550
+10,89 %
+10,89 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,650 | 5,800 | 22:51 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:17 | HSI Closes at 21,909, Down 162 pts; HSTI Closes at 4,975, Down 73 pts; MEITUAN Down over 5%; ASCENTAGE, AKESO, CHICMAX, CQRC BANK, NISSIN FOODS Hit New Highs; Market Turnover Rises | 5 | AASTOCKS | ||
| 01:06 | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin | 2 | GlobeNewswire (USA) | ||
| 01:05 | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT DATA FROM TWO CLINICAL STUDIES AT 2025 ASCO ANNUAL MEETING, INCLUDING ORAL PRESENTATION ... | 1 | HKEx | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| Mo | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mo | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA ANNOUNCES INCLUSION OF LISAFTOCLAX AND OLVEREMBATINIB IN CHINESE SOCIETY OF CLINICAL ONCOLOGY ... | 1 | HKEx | ||
| Mo | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines | 471 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing... ► Artikel lesen | |
| 16.04. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 16.04. | ASCENTAGE-B (06855): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 16.04. | ASCENTAGE-B (06855): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 19, 2025 | 1 | HKEx | ||
| 16.04. | ASCENTAGE-B (06855): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 16.04. | ASCENTAGE-B (06855): PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND NOTICE ... | - | HKEx | ||
| 16.04. | ASCENTAGE-B (06855): ANNUAL REPORT 2024 | - | HKEx | ||
| 08.04. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.04. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | 1 | HKEx | ||
| 31.03. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| 27.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.03. | Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan | 5 | Benzinga.com | ||
| 27.03. | Ascentage Pharma Group International GAAP EPS of -$0.18, revenue of $134.3M | 1 | Seeking Alpha | ||
| 27.03. | ASCENTAGE-B (06855): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 | 1 | HKEx | ||
| 27.03. | JPMorgan sets Ascentage Pharma stock to Overweight, $27 target | 4 | Investing.com |
Seite:
1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 53,50 | +7,93 % | Tempus AI: Deal mit Pharma-Riesen - Aktie geht steil | Für den AKTIONÄR ist klar: Künstliche Intelligenz (KI) wird auch in der Forschung und Entwicklung von Medikamenten mittel- bis langfristig sein disruptives Potenzial entfalten. Ein Player, der diesen... ► Artikel lesen | |
| EVOTEC | 7,344 | +1,75 % | EQS-News: Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024 | EQS-News: Evotec SE
/ Schlagwort(e): Jahresbericht
Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024
17.04.2025... ► Artikel lesen | |
| QIAGEN | 37,610 | +0,17 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,170 | +1,51 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 44,990 | +9,28 % | Barclays maintains SpringWorks stock at Overweight, $63 target | ||
| ARCELLX | 63,97 | +0,63 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 36,680 | +10,18 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
| BIONTECH | 102,20 | +0,79 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,400 | +3,91 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
| VERA THERAPEUTICS | 23,470 | +5,20 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,290 | +5,54 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,750 | +3,23 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
| ADMA BIOLOGICS | 22,340 | +2,71 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 3,190 | +2,74 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 5,100 | +2,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen |
ASCENTAGE PHARMA GROUP INTERNATIONAL gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,600 Euro und damit +10,89 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.
